Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

UCB S.A.

UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.


Contact Details:
Allée de la Recherche, 60
Brussels
1070
Belgium
Tel:32/2/559.99.99
Fax:32/2/559.99.00
Email:contactucb@UCB-Group.com
WWW:

www.medeva.co.uk/




Recent Publications by UCB S.A.:

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory illness...
10th October, 2009
UCB S.A., Andelecht, Belgium. Aliment Pharmacol Ther. 2009 May 1;29(9):1032-41.
DOI Direct Link
Visualization of SV2A conformations in situ by the use of Protein Tomography.
The synaptic vesicle protein 2A (SV2A), the brain-binding site of the...
28th October, 2008
Department of Molecular and Cellular Sciences, UCB S.A., Granta Park, Biochem Biophys Res Commun. 2008 Oct 31;375(4):491-5. Epub 2008 Aug 8.
DOI Direct Link
2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
A new series of 2,6-quinolinyl derivatives was prepared leading to potent...
25th April, 2007
UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium. Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10.
DOI Direct Link
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
High-throughput screening of the UCB sample collection identified the...
25th April, 2007
CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A., Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5.
DOI Direct Link
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.
A protocol for inducing cortical spreading depression (SD) on rat...
3rd February, 2007
UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium. Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11.
DOI Direct Link

View more UCB S.A. research publications.

Press Releases on UCB S.A.:

BioPortfolio Logo
Reportlinker Adds Regenerative Medicines: Bone and Joint Applications 3rd November, 2009 Reportlinker
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Regenerative Medicines: Bone and Joint Applications http://www.reportlinker
Shire Continues to Deliver Excellent Growth From Core Products 30th October, 2009
DUBLIN, October 30 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009. Q3 2009
Shire begins the year with a strong performance 30th April, 2009
PHILADELPHIA and DUBLIN, April 30 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to March 31, 2009.
Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 31st July, 2008 Barr Pharmaceuticals, Inc.
MONTVALE, N.J., July 31 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R) 6th June, 2008 UCB
SMYRNA, Ga., June 6 /PRNewswire/ -- UCB announced today that the US Food and Drug Administration (FDA) has granted pediatric exclusivity for Keppra(R) (levetiracetam). The decision was based on

UCB S.A. Patents:

US Patent No.Title
6420460 Cationically curable compositions containing triarylcyclopropenylium salts
6624218 Plasticized polymer compositions
6630565 Phosphorus-comprising materials, their preparation and use
6635721 Powder coating of semicrystalline and amorphous polyesters with crosslinker
6660398 Powder thermosetting compositions for preparing coatings with low gloss finish

View more UCB S.A. patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 16 individuals from UCB S.A. using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 310 times since April 2007, the link to the organisation's website has been followed 41 times

Recent Search Terms used to find this page: SA MEDEVA A BRAINE L ALLEUD | .

Search for more companies in Brussels

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for UCB S.A.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.